Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients.

Mayte Gil-CandelJuan José Gascón CánovasRosa Gómez EspínIsabel Nicolás de PradoLorena Rentero RedondoElena Urbieta SanzCarles Iniesta-Navalón

Published in: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva (2021)

the application of a population pharmacokinetic model based on Bayesian prediction is an important advance in the optimization of infliximab dosage in the treatment of inflammatory bowel disease.

Keyphrases

end stage renal disease
ulcerative colitis
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis